1. Ashton GA, Griffiths SA, McAuslane JAN (1999) Industry experience with alternative models for the carcinogenicity testing of pharmaceuticals. Centre for Medicines Research International, Surrey, U.K.
2. Baille TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, Shipley LA (2002) Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188–196
3. Bakke OM, Manocchia MA, deAbajo F, Kaitin KI, Lasagna L (1995) Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther 58:108–117
4. Bass R, Scheibner E (1987) Toxicological evaluation of biotechnology products: a regulatory viewpoint. Arch Toxicol Suppl 11:182–190
5. Beary JF III (1997) The drug development and approval process. In New drug approvals in 1997. Pharmaceutical Research and Manufacturers of America, Washington, DC